Oxybutynin and the overactive bladder

World Journal of Urology

Volumn 19, Issue 5, 2001, Pages 319-323

  Andersson, K E ^a   Chapple, C R ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Urinary incontinence antimuscarinic controlled release intravesical

Indexed keywords

MANDELIC ACID DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN;

BLADDER; BLADDER DISEASE; DRUG EFFECT; HUMAN; REVIEW;

BLADDER; BLADDER DISEASES; HUMAN; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS;

EID: 0035513922     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007103     Document Type: Article

References (60)

1. Amarenco G, Marquis P, McCarthy C, et al (1998) Qualité de vie des femmes souffrant d'mpériosité mictionelle avec ou sans fuites: étude prospective après traitement par oxybutinine (1701 cas). Presse Med 27: 5
2. Andersen RU, Mobley D, Blank B, et al (1999) Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 161: 1809
3. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, Roach M, Miklos J, Saltzstein D, Boone T. Staskin DR, Albrecht D: Overactive Bladder: Judging Effective Control and Treatment Study Group (2001) Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 76: 358
4. Baigrie RJ, Kelleher JP, Fawcett DP, et al (1988) Oxybutynin: is it safe? Br J Urol 62: 319
5. Birns J, Lukkari E, Malone-Lee JG (2000) A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose
6. symptoms were stabilized on 5 nig twice daily of oxybutynin BJU Int 85: 793
7. Brendler CB, Radebaugh LC, Mohler JL (1989) Topical oxybutynin chloride for relaxation of dysfunctional bladders. J LIrol 141: 1350
8. Buyse G, Verpoorten C, Vereecken R, et al (1995) Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self)catheterisation and optimized intravesical oxybutynin hydrochloride therapy. Eur J Pediatr Surg 5 [Suppl 1]: 31
9. Cardozo LD, Cooper D, Versi E (1987) Oxybutynin chloride in the management of idiopathic detrusor instability. Neurourol Urodyn 6: 256
10. Chancellor MB. Appell RA. Sathyan G. Gupta SK (2001) A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin Ther 23: 753
11. Collas D, Malone-Lee JG (1997) The pharmacokinetic properties of rectal oxybutynin - a possible alternative to intravesical administration. Neurourol Urodyn 16: 346
12. Comer AM, Goa KL (2000) Extended-release oxybutynin. Drugs Aging 16: 149
13. Donnellan CA, Fook L, McDonald P, et al (1997) Oxybutynin and cognitive dysfunction. BMJ 315: 1363
14. Douchamps J, Derenne F, Stockis A, et al (1988) The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35: 515
15. Enzelsberger H, Helmer H, Kurz C (1995) Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br J Obstet Gynaecol 102: 929
16. Ferrara P, D'Aleo CM, Tarquini E, et al (2001) Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int 87: 674
17. Gajewski JB, Awad SA (1986) Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 135: 966
18. Goldenberg MM (1999) An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther 21: 634
19. Gupta SK, Sathyan G (1999) Pharmacokinetics of an oral once-aday controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 39: 289
20. Hehir M, Fitzpatrick JM (1985) Oxybutynin and prevention of urinary incontinence in spina bifida. Eur Urol 11: 254
21. Holmes DM, Montz FJ, Stanton SL (1989) Oxybutinin versus propantheline in the management of detrusor instability. A patientregulated variable dose trial. Br J Obstet Gynaecol 96: 607
22. Hughes KM, Lang JCT, Lazare R, et al (1992) Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 22: 859
23. Hussain RM, Hartigan-Go K, Thomas SHL, et al (1994) Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 37: 485
24. Iselin CE, Schmidlin F, Borst F, et al (1997) Oxybutynin in thé treatment of early detrusor instability after transurethral resection of the prostate. Br J Urol 79: 915
25. Jonville AP, Dutertre JP, Autret E, et al (1992) Effets indésirables du chlorure d'oxybutynine (Ditropan®). Thérapie 47: 389
26. Kachur JF, Peterson JS, Carter JP, et al (1988) R and S enantiomers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J Pharmacol Exp Ther 247: 867
27. Kaplinsky R, Greenfield S, Wan J, et al (1996) Expanded followup of intravesical oxybutynin use in children with neurogenic bladder. J Urol 156: 753
28. Kasabian NG, Vlachiotis JD, Lais A, et al (1994) The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J Urol 151: 944
29. Katz IR, Sands LP, Bilker W, et al (1998) Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 46: 8
30. Kim YH, Bird ET, Priebe M, et al (1997) The role of oxybutynin in spinal cord injured patients with indwelling catheters. J Urol 158: 2083
31. Lose G, N0rgaard JP (2001) Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. B.IÜ Int XT. 767
32. Madcrsbacher H, Jilg G (1991) Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 29: 84
33. Madersbacher H. Knoll M (1995) Intravesical application of oxybulynin: mode of action in controlling detrusor hyperreflexia. Eur Urol 28: 340
34. Malone-Lee J, Lubel D, Szonyi G (1992) Low dose oxybutynin for the unstable bladder. BMJ 304: 1053
35. Mizunaga M, Miyata M, Kaneko S, et al (1994) Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neurogenic bladder. Paraplegia 32: 25
36. Moisey CU, Stephenson TP. Brendler CB (1980) The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 52: 472
37. Moore K.H, Hay DM, Imrie AE, et al (1990) Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 66: 479
38. Nilsson CG, Lukkari E, Haarala M, et al (1997) Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourol Urodyn 16: 533
39. Nilvebrant L, Sparf B (1986) Dicyclomine, benzhexol and oxybutynin distinguish between subclasses of muscarinic binding sites. Eur J Pharmacol 123: 133
40. Nilvebrant L, Andersson K-E, Mattiasson A (1985) Characterization of the muscarinic cholinoceptors in the human detrusor. J Urol 134: 418
41. Norhona-Blob L, Kachur JF (1991) Enantiomers of oxybutynin: in vitro pharmacological characterization at Ml, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther 256: 562
42. O'Flynn KJ, Thomas DG (1993) Intravesicular instillation of oxybutinin hydrochloride for detrusor hyperreflexia. Br J Urol 72: 566
43. Ouslander JG, Blaustein J. Connor A, et al (1988) Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 140: 47
44. Ouslander JG, Schnelle JF, Uman G, et al (1995) Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebocontrolled trial. J Am Geriatr Soc 43: 610
45. Palmer LS. Zeboid K., Firlit CF. et al (1997) Complications of intravesical oxybutynin chloride therapy in the pédiatrie myelomeningocele population. J Urol 157: 638
46. Sathyan G. Hu W, Gupta SK (2001) Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. J Clin Pharmacol 41: 187
47. Szollar SM, Lee SM (1996) Intravesical oxybutynin for spinal cord injury patients. Spinal Cord 34: 284
48. Szonyi G, Collas DM, Ding YY, et al (1995) Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Aging 24: 287
49. Tapp AJS, Cardozo LD, Versi E, et al (1990) The treatment of detrusor instability in post menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 97: 521
50. Thompson IM, Lauvetz R (1976) Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology 8: 452
51. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J. Heidler H, Madersbacher H, Melchior H, Schafer W, et al (1991) Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.! Urol 145: 813
52. Thuroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U, Palmtag H, Tanagho EA (1998) Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16 [Suppl 1]: S48
53. Tincello DG, Adams EJ, Sutherst JR, et al (2000) Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. BJU Int 85: 416
54. Versi E, Appell R, Mobley D, et al (2000) Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 95:718
55. Waldeck K, Larsson B, Andersson K-E (1997) Comparison of oxybutynin and its active metabolite. N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 157: 1093
56. Weese DL. Roskamp DA, Leach GE, et al (1993) Intravesical oxybutynin chloride: experience with 42 patients. Urology 41: 527
57. Winkler HA. Sand PK (1998) Treatment of detrusor instability with oxybutynin rectal suppositories. Int Urogynecol J Pelvic Floor Dysfunct 9: 100
58. Yarker YE, Goa KL, Fitton A (1995) Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6: 243
59. Zeegers AGM, Kiesswetter H, Kramer AEJ, et al (1987) Conservative therapy of frequency, urgency and urge incontinence: a double-blind clinical trial of flavoxate hydrochloride, oxybutinin chloride, emepronium bromide and placebo. World J Urol 5: 57
60. Zobrist RH, Schmid B, Feick A, Quan D, Sanders SW (2001) Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 18: 1029